REPATH LAUNCH
15 September 2026
Global
Genspect's REPATH campaign formally launched on 15 September 2026, calling for the restoration of psychiatric and psychological frameworks in the assessment of transgender ideation. Hosts Stella O'Malley and Mia Hughes discuss what re-psychopathologisation means in practice: not pathologising gender non-conformity, but ensuring thorough differential diagnosis before any clinical intervention. Multiple European systematic reviews — from the UK, Sweden, Finland and Denmark — have already found the evidence base for paediatric gender medicine to be very low, prompting treatment restrictions. REPATH asks professional bodies and health ministries to act on that evidence.
On 15 September 2026, Genspect formally launched REPATH — its Re-psychopathologisation Campaign — a structured international effort calling for the restoration of psychiatric and psychological frameworks in the clinical assessment of transgender ideation. Stella O'Malley and Mia Hughes dedicated the episode to marking the launch, explaining what the campaign demands, why it is now necessary, and what it asks of clinicians, professional bodies and health ministries across Europe and beyond. REPATH is precise in what it targets. The campaign does not call for the pathologisation of gender non-conformity. It argues that transgender ideation — a sustained belief that one's sex should be different — requires thorough psychiatric assessment and differential diagnosis before any clinical pathway is pursued. That distinction matters clinically. Systematic reviews in multiple countries have found that gender-distressed young people present with high rates of co-occurring anxiety, depression, autism spectrum conditions and trauma histories, all of which require their own assessment and treatment irrespective of any gender-related pathway. The evidence for that clinical picture has been assembled over several years by independent review bodies. The UK NICE evidence review (2020), Sweden's SBU report (2022), Finland's COHERE assessment (2020) and Denmark's Sundhedsstyrelsen evaluation all concluded that the quality of evidence for puberty blockers and cross-sex hormones in adolescents was very low to low — insufficient to support routine clinical use. Each review flagged the absence of long-term follow-up data and the failure to systematically assess co-occurring mental health conditions before treatment. Sweden, Finland, Norway and Denmark subsequently restricted or halted paediatric gender medicine on the basis of those findings. The removal of gender incongruence from the mental disorders chapter of the ICD-11 in 2022 sits at the centre of this debate. Proponents argued the reclassification reduced stigma; those behind REPATH contend it simultaneously removed the clinical scrutiny that a mental health framework provides, making differential diagnosis easier to bypass in affirmation-first settings. The campaign calls on professional bodies to re-examine that classification decision in light of the accumulated evidence from independent reviews and from real-world clinical outcomes now coming into view. The Cass Review, published in the UK in April 2024, reached closely related conclusions through a comprehensive examination of the clinical evidence and the historical development of gender services. It found the evidence base supporting medical transition for children and adolescents to be remarkably weak, psychological assessment to have been systematically under-resourced, and an affirmation-only model to have taken hold without adequate scrutiny. Its recommendations — thorough holistic assessment, research-only pathways for medical interventions, and investment in psychological support — align with what REPATH is now demanding at European and international level. O'Malley and Hughes situate the launch within a broader clinical and regulatory shift already under way across Europe. What the campaign adds is a formal, organised demand: that professional bodies, health ministries and clinical guidelines explicitly restore the psychiatric framework that governed this area of medicine before the affirmation model displaced it. Whether the institutions that set clinical standards will respond is now the central question.
